Chai is building foundation models for drug discovery, specifically to predict interactions between molecules so they could be reprogramed for cures.
OpenAI-backed biotech firm Chai Discovery raises $130M Series B at $1.3B valuation
Published 7 hours ago
Source: techcrunch.com
Categories
AIBiotech & Healthartificial intelligenceChai DiscoveryIn BriefOpenAIventure capital
Related Articles from techcrunch.com
6 hours ago
VCs discuss why most consumer AI startups still lack staying power
8 hours ago
I hate that I love Riverside’s AI-driven ‘Rewind’ for podcasters
9 hours ago
Disney’s OpenAI deal is exclusive for just one year — then it’s open season
9 hours ago
Nvidia bulks up open source offerings with an acquisition and new open AI models
10 hours ago
Ford is starting a battery storage business to power data centers and the grid
10 hours ago